Covalon Technologies Ltd. (TSXV:COV)

Market Cap	107.16M +86.1%
Revenue (ttm)	34.35M +4.1%
Net Income	4.39M +89.7%
EPS	0.16 +84.9%
Shares Out	27.62M
PE Ratio	24.37
Forward PE	20.16
Dividend	0.15 (3.77%)
Ex-Dividend Date	Nov 4, 2025

Volume	7,368
Open	3.900
Previous Close	3.880
Day's Range	3.750 - 4.090
52-Week Range	1.550 - 4.590
Beta	0.14
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 16, 2026

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company’s platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secon...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2004
• Employees: 37
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: COV

Financial Performance

In fiscal year 2025, Covalon Technologies's revenue was 32.82 million, an increase of 5.29% compared to the previous year's 31.17 million. Earnings were 2.06 million, a decrease of -22.91%.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Oct 2, 2026

Data Sources Report a data error